Patients with pulmonary arterial hypertension experienced a significant improvement in World Health Organization Functional Class when transitioned from a phosphodiesterase type 5 inhibitor to riociguat.
Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.
Performing therapeutic bronchoscopy at the time of intensive care unit admission may decrease ventilator-associated pneumonia incidence in patients with level I trauma.
PVX108, a peptide-based immunotherapy in development for the treatment of peanut allergy, demonstrated a favorable safety profile.
Researchers sought to determine whether a multidisciplinary SABA reduction program would significantly increase the percentage of patients who reached an AMR ≥0.5.
Patients who were actively treated with AR101, an investigational oral biologic with a characterized peanut protein profile, reported accidental exposure to peanut less often, had fewer associated adverse events, and required less rescue medication compared with placebo.
Quality of sleep significantly improved in patients with allergic rhinitis who were treated with the house dust mite (HDM) sublingual immunotherapy-tablet (12 SQ-HDM), according to a post hoc analysis.
